The pharmacodynamics of L-arginine

Alternative Therapies in Health and Medicine

Volumn 20, Issue 3, 2014, Pages 48-54

  Böger, Rainer H ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DIMETHYLARGININE; DRUG DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; HUMAN; METABOLISM; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ARGININE; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 84904062805     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Rose WC. The nutritive significance of the amino acids. Physiol Rev. 1938;18(1):109-136.
2. Natural Standards Patient Monograph. Drugs and supplements: arginine. Mayo Clinic Web site. http://www.mayoclinic.org/drugs-supplements/arginine/background/ hrb-20058733. Updated November 1, 2013. Accessed February 15, 2014.
3. Koga Y, Akita Y, Nishioka J, et al. MELAS and L-arginine therapy. Mitochondrion. 2007;7(1-2):133-139
4. Vadillo-Ortega F, Perichart-Perera O, Espino S, et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ. May 2011;342:d2901.
5. Dong JY, Qin LQ, Zhang Z, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J. 2011;162(6):959-965.
6. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336(pt 1):1-17.
7. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329(27):2002-2012.
8. Förstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes: characterization, purification, molecular cloning, and functions. Hypertension. 1994;23(6, pt 2):1121-1131.
9. Förstermann U, Boissel JP, Kleinert H. Expressional control of the ‘constitutive’ isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 1998;12(10):773-790.
10. Zembowicz A, Hecker M, Macarthur H, Sessa WC, Vane JR. Nitric oxide and another potent vasodilator are formed from NG-hydroxy-L-arginine by cultured endothelial cells. Proc Natl Acad Sci U S A. 1991;88(24):11172-11176.
11. Bohme GA, Bon C, Lemaire M, et al. Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. Proc Natl Acad Sci U S A. 1993;90(19):9191-9194.
12. Paakkari I, Lindsberg P. Nitric oxide in the central nervous system. Ann Med. 1995;27(3):369-377.
13. Böger RH, Bode-Böger SM, Frölich JC. The L-arginine - nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis. 1996;127(1):1-11.
14. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489-509.
15. Cooke JP. The pivotal role of nitric oxide for vascular health. Can J Cardiol. 2004;20(suppl B):7B-15B.
16. Li XA, Everson W, Smart EJ. Nitric oxide, caveolae, and vascular pathology. Cardiovasc Toxicol. 2006;6(1):1-13.
17. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitric oxide and atherosclerosis: an update. Nitric Oxide. 2006;15(4):265-279.
18. Kilbourn RG, Szabo C, Traber DL. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Shock. 1997;7(4):235-246.
19. Viol AW, Prewitt RL, Doviak M, Britt LD. Endotoxin releases a substance from the aorta that dilates an isolated arteriole by up-regulating INOS. J Surg Res. 2005;127(2):106-111.
20. Silk DB, Grimble GK, Rees RG. Protein digestion and amino acid and peptide absorption. Proc Nutr Soc. 1985;44(1):63-72.
21. Souci SW, Fachmann W, Kraut H. Food Composition and Nutrition Tables. 5th. Stuttgart, Germany: Medpharm Scientific Publishers; 1994.
22. Möller P, Bergström J, Eriksson S, Furst P, Hellström K. Effect of aging on free amino acids and electrolytes in leg skeletal muscle. Clin Sci (Lond). 1979;56(5):427-432.
23. Möller P, Alvestrand A, Bergström J, Furst P, Hellström K. Electrolytes and free amino acids in leg skeletal muscle of young and elderly women. Gerontology. 1983;29(1):1-8.
24. Bogle RG, MacAllister RJ, Whitley GS, Vallance P. Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol. 1995;269(3, pt 1):C750-C756.
25. Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000;87(2):99- 105.
26. Schmidt HH, Nau H, Wittfoht W, et al. Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol. 1988;154(2):213-216.
27. Castillo L, deRojas TC, Chapman TE, et al. Splanchnic metabolism of dietary arginine in relation to nitric oxide synthesis in normal adult man. Proc Natl Acad Sci U S A. 1993;90(1):193-197.
28. Böger RH, Tsikas D, Bode-Böger SM, Phivthong-Ngam L, Schwedhelm E, Frölich JC. Hypercholesterolemia impairs basal nitric oxide synthase turnover rate: a study investigating the conversion of L-[guanidino-15N2]-arginine to 15N-labeled nitrate by gas chromatography-mass spectrometry. Nitric Oxide. 2004;11(1):1-8.
29. Merimee TJ, Rabinovitz D, Riggs L, Burgess JA, Rimoin DL, McKusick VA. Plasma growth hormone after arginine infusion: clinical experiences. N Engl J Med. 1967;276(8):434-439.
30. Bode-Böger SM, Böger RH, Creutzig A, et al. L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci (Lond). 1994;87(3):303-310.
31. Bode-Böger SM, Böger RH, Alfke H, et al. L-arginine induces nitric oxidedependent vasodilation in patients with critical limb ischemia: a randomized, controlled study. Circulation. 1996;93(1):85-90.
32. Bode-Böger SM, Böger RH, Galland A, Tsikas D, Frölich JC. L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol. 1998;46(5):489-497.
33. Böger RH, Mügge A, Bode-Böger SM, Heinzel D, Höper M, Frölich JC. Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension. Int J Clin Pharmacol Ther. 1996;34(8):323-328.
34. Bode-Böger SM, Böger RH, Löffler M, Tsikas D, Brabant G, Frölich JC. L-arginine stimulates NO-dependent vasodilation in healthy humans—effect of somatostatin pretreatment. J Investig Med. 1999;47(1):43-50.
35. Giugliano D, Marfella R, Verazzo G, et al. The vascular effects of L-arginine in humans: the role of endogenous insulin. J Clin Invest. 1997;99(3):433-438.
36. Roh SG, Koiwa K, Sato K, Ohtani Y, Takahashi T, Katoh K. Actions of intravenous injections of AVP and oxytocin on plasma ACTH, GH, insulin and glucagon concentrations in goats. Anim Sci J. 2014;85(3):286-292.
37. Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens. 1993;7(2):193-194.
38. Bode-Böger SM, Muke J, Surdacki A, Brabant G, Böger RH, Frölich JC. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med. 2003;8(2):77-81.
39. Böger RH, Bode-Böger SM. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol. 2001;41:79-99.
40. Jeserich M, Münzel T, Just H, Drexler H. Reduced plasma L-arginine in hypercholesterolaemia [letter]. Lancet. 1992;339(8792):561.
41. Morris SM Jr Enzymes of arginine metabolism. J Nutr. 2004;134(10) (suppl):2743S-2747S.
42. Bachetti T, Comini L, Francolini G, et al. Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol. 2004;37(2):515-523.
43. Berkowitz DE, White R, Li D, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 2003;108(16):2000-2006.
44. Xu W, Kaneko FT, Zheng S, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 2004;18(14):1746-1748.
45. Zhang C, Hein TW, Wang W, et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension. 2004;44(6):935-943.
46. Chicoine LG, Paffett ML, Young TL, Nelin LD. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2004;287(1):L60-L68.
47. Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003;59(4):824-833.
48. Böger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med. 2006;38(2):126-136.
49. Böger RH, Ron ES. L-arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev. 2005;10(1):14-23.
50. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 1991;338(8782-8783):1546-1550.
51. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol. 1997;80(3):331-333.
52. Bednarz B, Wolk R, Chamiec T, Herbaczynska-Cedro K, Winek D, Ceremuzynski L. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. Int J Cardiol. 2000;75(2-3):205-210.
53. Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation. 1996;93(12):2135-2141.
54. Bednarz B, Jaxa-Chamiec T, Gebalska J, Herbaczynska-Cedro K, Ceremuzynski L. L-Arginine supplementation prolongs exercise capacity in congestive heart failure. Kardiol Pol. 2004;60(4):348-353.
55. Blum A, Hathaway L, Mincemoyer R, et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation. 2000;101(18):2160- 2164.
56. Walker HA, McGing E, Fisher I, et al. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol. 2001;38(2):499-505.
57. Dudek D, Legutko J, Heba G, et al. L-arginine supplementation does not inhibit neointimal formation after coronary stenting in human beings: an intravascular ultrasound study. Am Heart J. 2004;147(4):E12.
58. Fayh AP, Krause M, Rodrigues-Krause J, et al. Effects of L-arginine supplementation on blood flow, oxidative stress status and exercise responses in young adults with uncomplicated type I diabetes. Eur J Nutr. 2013;52(3):975-983.
59. Alvares TS, Conte CA, Paschoalin VM, et al. Acute L-arginine supplementation increases muscle blood volume but not strength performance. Appl Physiol Nutr Metab. 2012;37(1):115-126.
60. Alvares TS, Conte-Junior CA, Silva JT, Paschoalin VM. L-arginine does not improve biochemical and hormonal response in trained runners after 4 weeks of supplementation. Nutr Res. 2014;34(1):31-39.
61. Böger RH. L-arginine therapy in cardiovascular pathologies: beneficial or dangerous? Curr Opin Clin Nutr Metab Care. 2008;11(1):55-61.
62. Bednarz B, Jaxa-Chamiec T, Maciejewski P, et al. Efficacy and safety of oral l-arginine in acute myocardial infarction: results of the multicenter, randomized, double- blind, placebo-controlled ARAMI pilot trial. Kardiol Pol. 2005;62(5):421-427.
63. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006;295(1):58-64.
64. McEniery CM, Wallace S, Mackenzie IS, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension. 2006;48(4):602-608.
65. Abumrad NN, Barbul A. Arginine therapy for acute myocardial infarction [letter]. JAMA. 2006;295(18):2138-2139.
66. Böger RH. Letter to the editor re: JAMA article on L-arginine therapy in acute myocardial infarction. Altern Med Rev. 2006;11(2):91-92.
67. Lee J, Ryu H, Ferrante RJ, Morris SM Jr, Ratan RR. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A. 2003;100(8):4843-4848.
68. Morris SM Jr. Arginine metabolism in vascular biology and disease. Vasc Med. 2005;10(suppl 1):S83-S87.
69. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med. 2005;10(suppl 1):S49-S57.
70. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med. 2004;42(12):1377-1383.
71. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Böger RH. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest. 2005;35(10):622-626.
72. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem. 2005;51(7):1268- 1271.
73. Velickovic K, Markelic M, Golic I, et al. Long-term dietary L-arginine supplementation increases endothelial nitric oxide synthase and vasoactive intestinal peptide immunoexpression in rat small intestine [published online ahead of print October 8, 2013]. Eur J Nutr.